Danielle Large, PhD

Assistant Editor of Molecular Cancer Therapeutics @MCT_AACR
published by @AACR. @Northeastern alum. Views are my own.

[Molecular Cancer Therapeutics @MCT_AACR]

David Rimm presenting data from his @MCT_AACR simultaneous publication at #AACR26. @yalepathology

[Molecular Cancer Therapeutics @MCT_AACR]

Congratulations to Chris Carosino and colleagues on their simultaneous publication—An Integrin β6-Targeted ADC Optimized for Intravesical Delivery to Treat Non-Muscle Invasive Bladder Cancer—presented at #AACR26. Read the article: https://t.co/dWuiX3QHdN
#OpenAccess

[Molecular Cancer Therapeutics @MCT_AACR]

Online now! Simultaneous publication with an @AACR Annual Meeting 2026 Advances in Technologies Session: Quantification of Antibody-Drug Conjugate Targets in Head and Neck Squamous Cell Carcinoma https://t.co/RtN2cILnpE #AACR26

[Molecular Cancer Therapeutics @MCT_AACR]

Had a great Meet-the-Editor session at #AACR26 with
@MCT_AACR Editor-in-Chief Daniel K. Nomura and Associate Editor Danielle Large!

[Molecular Cancer Therapeutics @MCT_AACR]

Online now! Simultaneous publication with an @AACR Annual Meeting 2026 poster: An Integrin β6-targeted antibody-drug conjugate optimized for intravesical delivery to treat non-muscle invasive bladder cancer https://t.co/y42c5e8a4h
#OpenAccess #AACR26

[Molecular Cancer Therapeutics @MCT_AACR]

Online now! Simultaneous publication with an #AACR26 poster: #FirstDisclosure of ABL209 (NEOK002), an EGFRxMUC1 bispecific TOP1i ADC with promising anti-tumor activity and enhanced therapeutic window https://t.co/lqrM70OLkH

[Molecular Cancer Therapeutics @MCT_AACR]

Attending #Targets25? Read this collection of articles that features recent research and review articles highlighting key advances in PROTAC and molecular glue development.
https://t.co/KnwvIfxxwb

[Molecular Cancer Therapeutics @MCT_AACR]

Curious about opportunities to publish in AACR Journals? Visit AACR booth 101 at #Targets25 on October 24 at 1PM to chat with Molecular Cancer Therapeutics Associate Editor Danielle Large, PhD, about your research.

[Molecular Cancer Therapeutics @MCT_AACR]

Heading to Concurrent Session 3: Protein Degraders at #Targets25? Be sure to check out the new @AACR Journals collection—Advances in Targeted Protein Degradation: PROTACs and Molecular Glues https://t.co/69qrc5b2Gp

[Molecular Cancer Therapeutics @MCT_AACR]

Online now concurrent with a #Targets25 poster, the #FirstDisclosures of G12D-HSP90 dual inhibitors:
Dual Inhibitors of #KRASG12D and #HSP90 Are Effective Against KRASG12D Inhibitor Resistance, by @LabShimamura https://t.co/SyxPAlEAih
@UICancerCenter @AACR

[Molecular Cancer Therapeutics @MCT_AACR]

Molecular Cancer Therapeutics Assistant Editor Danielle Large, PhD, will be at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics. If you have a question about the journal or want to discuss your research, contact her at [email protected]. #Targets25

[Molecular Cancer Therapeutics @MCT_AACR]

Associate Editor @DanielleLarge2 is attending #ESMOTATAsia25. Reach out to her at [email protected] to schedule a meeting to discuss your ongoing research or to learn more about publishing at Molecular Cancer Therapeutics.

[Molecular Cancer Therapeutics @MCT_AACR]

Assistant Editor Danielle Large, PhD, is in Chicago attending the 2025 ASCO Annual Meeting and would love to hear about your research.

Connect with her to discuss your work and learn about submitting to the journal. #ASCO25

[Molecular Cancer Therapeutics @MCT_AACR]

Read the editorial from our new Editor-in-Chief @DanNomura, PhD—A Vision for the Future of Molecular Cancer Therapeutics. https://t.co/3hkvje7vet

[Molecular Cancer Therapeutics @MCT_AACR]

Online now. Simultaneous publication with an #AACR25 poster: The #FirstDisclosure of HBS-101, a novel inhibitor of midkine, as a therapeutic agent for the treatment of triple negative breast cancer: https://t.co/9RWkYUgG93
@AACR

[Molecular Cancer Therapeutics @MCT_AACR]

Timothy Yap presents his work on the ATR inhibitor elimusertib in tumors with DDR alterations (left), published concurrently with #AACR25, and is pictured with our Assistant Editor @DanielleLarge2 (right).

[Molecular Cancer Therapeutics @MCT_AACR]

Online now. Simultaneous publication with an #AACR25 poster: 6-((1,4-naphthoquinone-2-yl)methyl)thio-glucose conjugates, a novel targeted approach for advanced #prostatecancer. https://t.co/WCD8y9zrbP @AACR

[Molecular Cancer Therapeutics @MCT_AACR]

Online now! Simultaneous publication with an #AACR25 poster: Zidesamtinib Selective Targeting of Diverse ROS1 Drug-Resistant Mutations: https://t.co/btJrGfZxXC
@AACR

[Molecular Cancer Therapeutics @MCT_AACR]

Congratulations to corresponding author Robert Yuan and coauthor Genevive Hernandez, pictured here with Assistant Editor @DanielleLarge2.

[Molecular Cancer Therapeutics @MCT_AACR]

Pictured here are corresponding author Matthew R. Levengood, coauthor Christopher M. Carosino, and our Assistant Editor @DanielleLarge2. Congratulations to the authors.